Modulation of MicroRNAs by Phytochemicals in Cancer: Underlying Mechanisms and Translational Significance

Srivastava, Sanjeev K.; Arora, Sumit; Averett, Courey; Singh, Seema; Singh, Ajay P.

doi:https://doi.org/10.1155/2015/848710

BioMed Research International

On this page

Abstract Introduction Conclusion Acknowledgments References Copyright Related Articles

Special Issue

MicroRNAs: Emerging Novel Targets of Cancer Therapies

View this Special Issue

Review Article | Open Access

Volume 2015 | Article ID 848710 | https://doi.org/10.1155/2015/848710

Modulation of MicroRNAs by Phytochemicals in Cancer: Underlying Mechanisms and Translational Significance

Sanjeev K. Srivastava,¹Sumit Arora,¹Courey Averett,¹Seema Singh,¹and Ajay P. Singh^1,2

Academic Editor: Fumitaka Takeshita

Received26 Aug 2014

Accepted12 Oct 2014

Published17 Mar 2015

Abstract

MicroRNAs (miRNAs) are small, endogenous noncoding RNAs that regulate a variety of biological processes such as differentiation, development, and survival. Recent studies suggest that miRNAs are dysregulated in cancer and play critical roles in cancer initiation, progression, and chemoresistance. Therefore, exploitation of miRNAs as targets for cancer prevention and therapy could be a promising approach. Extensive evidence suggests that many naturally occurring phytochemicals regulate the expression of numerous miRNAs involved in the pathobiology of cancer. Therefore, an understanding of the regulation of miRNAs by phytochemicals in cancer, their underlying molecular mechanisms, and functional consequences on tumor pathophysiology may be useful in formulating novel strategies to combat this devastating disease. These aspects are discussed in this review paper with an objective of highlighting the significance of these observations from the translational standpoint.

1. Introduction

MicroRNAs (miRNAs) are endogenous, small noncoding RNA molecules that posttranscriptionally regulate gene expression. miRNAs bind to the 3′-UTRs of target mRNA with partial or complete complementarity, thus causing translational repression or target messenger RNA (mRNA) degradation [1]. An individual miRNA can regulate the expression of multiple genes; conversely, a single mRNA can be targeted by many miRNAs. To date, about 2,469 miRNAs have been identified in humans [2], and more than one-third of all human genes are potentially regulated by miRNAs [3]. Extensive studies have shown that miRNAs not only are involved in the process of cell development and differentiation but also play a critical role in carcinogenesis [4]. Emerging data suggest that several classes of naturally occurring, plant-derived compounds (phytochemicals) could potentially regulate the expression of several miRNAs involved in cancer.

Phytochemicals are nonnutritive plant chemicals that have various applications including anti-inflammatory and anticancer. These phytochemicals are widely distributed in various fruits, vegetables, herbs, beverages, and many other dietary supplements. Numerous studies have demonstrated that the intake of fruit- and vegetable-rich foods decreases the occurrence of cancer [5–7]. So far, more than 10,000 phytochemicals have been identified [8], and a significant number of phytochemicals show anticancer potential with no or minimal toxicity to normal cells [9]. Interestingly, around 47% of FDA approved anticancer drugs are derived from plants [10, 11]. Moreover, these phytochemicals could be used as a single chemotherapeutic agent or in association with standard anticancer drugs. Phytochemicals can increase the efficacy of anticancer drugs synergistically, while reducing the toxic side effects of the standard chemotherapeutic drugs [12, 13]. These phytochemicals exert their anticancer effects through modulation of multiple molecular targets affecting various signaling pathways [8, 14, 15]. In the present review paper, we focus our attention on the regulation of miRNAs by some of the phytochemicals such as resveratrol, epigallocatechin-3-gallate (EGCG), curcumin, camptothecin (CPT), and diindolylmethane (DIM) for cancer prevention and therapy.

2. Biogenesis of miRNA and Mechanism of Gene Silencing

The biosynthesis of miRNAs begins with gene transcription by RNA polymerase II or RNA polymerase III into primary miRNA (pri-miRNA) transcripts inside the nucleus. These pri-miRNAs are comprised of either a cluster or single miRNAs folded into a hairpin stem-like structure [1]. This long pri-miRNA is processed by the sequential, endonucleolytic cleavage of the transcript by the microprocessor complex, containing drosha and DGCR8, into a 65–70-nucleotide precursor miRNA (pre-miRNA). This pre-miRNA is then exported from the nucleus to the cytoplasm by the nuclear export factor Exportin-5/Ran-GTP and cleaved by RNase III endonuclease, Dicer/TRBP, and argonaute 2 (Ago2) miRNA duplex [16] into an ~22-nucleotide product. This duplex miRNA then unwinds to generate a single-stranded miRNA. One of the strands enters in the RNA-induced silencing complex (RISC) along with Ago proteins and directs the complex to target mRNA. This binding causes either target mRNA degradation or inhibition of translation [1].

3. Biological Significance of miRNAs in Cancer: Tumor Suppressors and Oncogenes

Based on in vitro and in vivo studies, miRNAs have been characterized as tumor suppressors or oncogenes. In this section we will discuss some of the reports from a long list of tumor suppressor/oncogenic miRNAs that have been experimentally validated.

Numerous studies have shown that the expression of the tumor suppressor Let-7 is significantly downregulated or lost in various cancers [17–19]. It has been shown that restoration of Let-7 inhibited tumor growth in a K-RAS lung cancer model [20]. Furthermore, decreased expression of let-7 correlated with shorter survival in non-small-cell lung cancer [21]. Other miRNAs such as miR-15a and miR-16 are either deleted or downregulated in most cases of the chronic lymphocytic leukemia, and their overexpression induced apoptosis [22]. Moreover, it has been reported that miR-16 and miR-15 were downregulated in multidrug-resistant human gastric cancer cells, and restoration of these miRNAs sensitized the cancer cells to chemotherapeutic drugs [23]. Takeshita and coworkers demonstrated the growth inhibitory role of miR-16 in prostate cancer cells [24]. The levels of miR-34 are significantly decreased in various cancers, and its restoration was reported to inhibit angiogenesis and malignant behavior, yet at the same time it induced apoptosis and cell cycle arrest [25, 26]. Additionally, the role of miR-34 in the inhibition of tumor-initiating cells has also been suggested [27]. In mixed lineage leukemia, the overexpression of miR-495 inhibited cell viability and reduced leukemogenesis in vivo [28]. In one of our recent studies, we investigated the significance of miR-150 downregulation in pancreatic cancer [29]. We demonstrated that the restoration of miR-150 inhibited the MUC4 oncoprotein. Consequently, the growth and malignant potential of pancreatic cancer cells were suppressed [29, 30]. The role of miR-451 as a tumor suppressor miRNA by inhibiting cancer cell migration, invasion, and growth is well known [31–33]. Further, Kovalchuk and coworkers demonstrated that miR-451 sensitizes MCF-7/DOX-resistant cells to doxorubicin cytotoxicity [34]. Xu and coworkers demonstrated that miR-203 overexpression effectively inhibited cell proliferation and induced apoptosis and cell cycle arrest. Moreover, its overexpression also inhibited tumor growth in a mouse model [35].

To date, several miRNAs have been identified that act as oncogenes [36]. miR-17-92 is an oncogenic gene cluster [37]; restoration of this cluster in MYC-driven B-cell lymphomas suppressed apoptosis and enhanced tumorigenicity [37]. Ma et al., 2010, demonstrated that miR-27a, which is overexpressed in pancreatic cancer, plays an oncogenic role by targeting tumor suppressor Spry2 [38]. Inhibition of miR-27a decreased growth, clonogenicity, and migration of pancreatic cancer cells. miR-21 is a widely studied oncogenic miRNA which is frequently overexpressed in various malignancies [39, 40]. Inactivation of miR-21 results in apoptosis induction, inhibition of growth, and malignant progression [39–41]. In a transgenic mice model, miR-155 induced polyclonal pre-B-cell proliferation resulting in B-cell leukemia [42]. miR-373 and miR-520c are known to promote migration, invasion, and metastasis of breast cancer cells by targeting CD44 expression [43]. Moreover, the roles of miR-373 and miR-520c in promoting migration and invasion of prostate cancer cells have also been reported [44]. In pancreatic cancer, miR-424-5p is overexpressed, and its high expression has been reported to be associated with enhanced proliferation and apoptosis resistance through downregulating SOCS6 [45]. miR-10b is overexpressed in various malignancies and promotes cell migration, invasion, and metastasis [46–48]. Moreover, a high expression of miR-10b correlated with disease progression [47, 49]. miR-221 and miR-222 are known to facilitate tumor cell growth, malignant potential, and EMT in multiple malignancies such as prostate, breast, and thyroid cancer [50–53].

Moreover, overexpression of miR-221 and miR-222 was shown to impart tamoxifen-resistance in breast cancer cells [54]. Altogether, these findings indicate that miRNAs play important roles as oncogenes in cancer cells.

4. Modulation of miRNAs by Phytochemicals

miRNAs are being considered as attractive targets for cancer prevention and therapy due to their oncogenic or tumor suppressor activities. Various studies have suggested that the modulation of miRNAs serves as one of the key mechanisms in the anticancer activities of a variety of phytochemicals (Table 1). Below, we describe some of the phytochemicals which are known to regulate miRNA expression in cancer.

4.1. Resveratrol

Resveratrol is a stilbenoid that has been shown to have anticancer activities against various cancers including breast cancer, lung cancer, glioma, prostate cancer, colon cancer, and neuroblastoma [55, 56]. Resveratrol reduced the expression of numerous oncogenic miRNAs, namely, miR-17, miR-21, miR-25, miR-92a-2, miR-103-1, and miR-103-2, in human colon cancer cells [57]. Moreover, in the same study, tumor suppressor miR-663 levels were shown to be restored in human colon cancer cells after the treatment of resveratrol. In another study, Hagiwara et al. reported that resveratrol treatment upregulated miR-141 and resulted in a significant reduction of invasiveness, whereas resveratrol-induced miR-200c expression caused reversal of EMT through downregulation of Zeb1 and upregulation of E-cadherin [58]. It has been demonstrated that the anticancer effect of resveratrol on pancreatic cancer cells was due to inhibition of oncogenic miR-21 [59]. Moreover, the synergistic antitumor activity of resveratrol and miR-200c has been demonstrated in human lung cancer cells [60]. In colon cancer cells, resveratrol inhibited the cell growth and induced apoptosis through upregulating miR-34a expression [61].

4.2. Epigallocatechin-3-gallate (EGCG)

Epigallocatechin-3-gallate is a polyphenol flavonoid that possesses significant antioxidant and anticancer properties. It has been shown that EGCG induces apoptosis in hepatocellular carcinoma through enhanced expression of miR-16 [62]. Increased expression of miR-16 resulted in inhibition of its target antiapoptotic Bcl-2, followed by mitochondrial dysfunction, cytochrome c release, and subsequent apoptosis. EGCG also inhibited the expression of miR-21 followed by repression of androgen receptor (AR) signaling and, consequently, a reduction of prostate cancer cell growth [63]. In lung cancer, EGCG upregulated the expression of miR-210, which led to the inhibition of proliferation and anchorage-independent growth [64]. EGCG enhanced the efficacy of cisplatin through downregulation of miR-98-5p in A549 non-small lung cancer cells [65]. A combination of N-(4-hydroxyphenyl) retinamide and EGCG decreased the expression of oncogenic miRs (miR-92, miR-93, and miR-106b) and enhanced the expression of tumor suppressor miRs (miR-7-1, miR-34a, and miR-99a) which resulted in growth inhibitory effects in human malignant neuroblastoma cells [66].

4.3. Genistein

Genistein is another important polyphenol that showed significant anticancer effects through the regulation of miRNAs. Genistein treatment was shown to enhance apoptosis synergistically with miR-16 in human chronic lymphocytic leukemia cells [67]. In a study on prostate cancer, genistein both downregulated miR-221 and miR-222 and restored tumor suppressor gene aplasia Ras homolog member I (ARHI) expression, which ultimately resulted in anticancer effects [68]. In another study on prostate cancer, genistein inhibited the migration and invasion of PC3 and DU145 cells through downregulating oncogenic miR-151 [69]. Xu et al. have shown that treatment of ovarian cancer cells with genistein caused an inhibition of cell growth and migration through suppression of miR-27a [70]. Further, genistein has been shown to upregulate the tumor suppressor miR-574-3p in prostate cancer cells [71]. Moreover, it has been observed that genistein exerted its antitumor effect in prostate cancer via downregulation of miR-1260b [72]. Genistein treatment downregulated oncogenic miR-1260b and resulted in inhibition of Wnt-signalling in renal cancer cells [72]. miR-223 expression was found to be downregulated in pancreatic cancer cells after genistein treatment that correlated with cell growth inhibition and induction of apoptosis [73]. Genistein also plays a tumor suppressor role through inhibition of miR-27a in pancreatic cancer cells [74].

4.4. Curcumin

Curcumin is a constituent of turmeric (Curcuma longa) and has been used as an important component of spice in Indian food and as a traditional medicine in Asian countries for many decades [75]. It possesses chemopreventive and chemotherapeutic activities against many tumors [75–78]. Curcumin exerts its therapeutic effects by regulating miRNAs known to play an important role in cancer [79]. Yang et al. have shown that curcumin upregulated miR-15a and miR-16 in MCF-7 breast cancer cells which caused an induction of apoptosis [80]. In another study, curcumin treatment resulted in the upregulation of tumor suppressor miR-203 in bladder cancer that led to apoptosis induction and diminished proliferation, migration, and invasion [81]. Curcumin has also been shown to induce tumor suppressor miR-186* expression to promote apoptosis in lung cancer [82]. Moreover, curcumin inhibited the transcriptional regulation of oncogenic miR-21 in colon cancer, causing inhibition of growth, invasion, and metastasis [83]. Zhao et al. provided evidence that curcumin exerts its cytotoxic effects against SKOV3 ovarian cancer cells largely through upregulation of miR-9 [84]. Another tumor suppressor, miR181b, has been demonstrated to be induced by curcumin, and it inhibited breast cancer metastasis via downregulation of the inflammatory cytokines CXCL1 and CXCL2 [85]. High levels of miR-221 expression have been correlated with shorter survival in pancreatic cancer patients, suggesting that miR-221 could be an oncogenic miRNA [86]. In the same study, the synthetic curcumin analogue (CDF) has been found to suppress the expression of miR-221 and upregulate the expression of PTEN, p27 (kip1), p57 (kip2), and PUMA, followed by inhibition of cell proliferation and migration of pancreatic cancer cells. Thus, altogether, these studies provide evidence that curcumin modulates the expression of miRNA signatures in cancer cells to confer its anticancer activity.

4.5. Quercetin

Intake of a quercetin-rich diet has been demonstrated to modulate the expression of 48 unique miRNAs. These miRNAs have been reported to decrease tumor metastasis and invasion (miR-146a/b, 503, and 194), inhibit cell proliferation (miR-125a, 155, let-7 family, 302c, 195, 26a, 503, and 215), induce apoptosis (miR-125a, 605, 26b, let-7g, 34a, 491, and 16), and upregulate tumor suppressor miRNAs (let-7 family, miR-125a, 183, 146a, 98, 19b, 106a, and 381) [87]. Del Follo-Martinez et al. reported that quercetin treatment induced apoptosis in colorectal cancer cells when used along with resveratrol. The underlying mechanism of apoptosis induction is the downregulation of oncogenic miR-27a [88]. In another study, quercetin, when used with catechins, was shown to enhance the expression of let-7 in pancreatic cancer cells followed by K-ras inhibition and reduction of the advancement of pancreatic cancer [89].

4.6. Camptothecin (CPT)

Camptothecin, an alkaloid isolated from bark of Camptotheca acuminata, is a potent chemotherapeutic agent against a variety of tumors [90–92]. CPT was demonstrated to reduce the expression of miR-125b significantly, which led to the upregulation of Bak1 and p53 and resulted in apoptosis of human cervical cancer and myelogenous leukemia cells [92]. In a recent study, camptothecin was shown to inhibit HIF-1α by enhancing the levels of miR-155, miR-17-5p, and miR-18a in HeLa cells [93].

4.7. Diindolylmethane (DIM)

Diindolylmethane is an active compound that is generated in the stomach through the metabolic conversion of indole-3-carbinol (I3C), present in cruciferous vegetables [94]. DIM regulates the expression of numerous miRNAs involved in cancer development and progression. DIM has been demonstrated to induce the expression of certain miRNAs, such as miR-200 and let-7 families, that led to the reversal of EMT and enhanced chemosensitivity in gemcitabine-resistant pancreatic cancer cells [95]. DIM also induced the expression of miR-146a, which resulted in reduced pancreatic cancer cell invasion via inhibition of metastasis-associated protein 2 (MTA-2), interleukin-1 receptor-associated kinase 1 (IRAK-1), and NFκB [96]. Moreover, Jin observed that DIM inhibited breast cancer cell growth by enhancing the expression of miR-21 which led to the degradation of its target Cdc25A [97]. Formulated 3,3′-diindolylmethane (BR-DIM) has been shown to be capable of downregulating miR-221, resulting in growth inhibition of pancreatic cancer cells [86].

5. Mechanism of miRNA Regulation by Phytochemicals

There have been several aberrantly expressed miRNAs identified in various cancer types. Unfortunately, the precise mechanisms that regulate the normal expression of miRNAs or their deregulation in cancer remain unclear. Growing evidence suggests that aberrant transcriptional regulation, epigenetic changes, alterations in miRNA biosynthesis machinery, mutations, or DNA copy number could contribute to miRNA dysregulation in human cancer [98]. Experimental studies on phytochemicals revealed that the expression of various miRNAs can be regulated by phytochemicals. In the following section, we provide an overview for the regulation of miRNAs by phytochemicals through various mechanisms such as epigenetic, transcriptional, and miRNA processing (Figure 1).

5.1. Transcriptional Regulation of miRNAs

Various studies indicate the involvement of certain transcription factors in the regulation of miRNA expression and the subsequent modulation of pathological conditions in cancer. Thus, transcription factor-mediated miRNA regulation is one critical aspect of study. Several groups have observed that phytochemicals modulate miRNA expression through transcriptional regulation (Figure 1). Wang and coworkers demonstrated that treatment with EGCG results in the transcriptional activation of miR-210 in lung cancer by promoting the binding of hypoxia inducible factor-1α (HIF-1α) to the hypoxia response element present in the promoter region of miR-210 [64]. Transcription factor activator protein (AP-1), an important regulator of genes involved in cell proliferation and extracellular matrix production [99], is an upstream regulator of miR-21 [100]. Mudduluru and coworkers demonstrated that curcumin inhibits the transcriptional regulation of miR-21 by downregulating AP-1 to suppress tumor growth, invasion, and metastasis of colorectal cancer [83]. Another transcription factor, CCAAT/enhancer binding protein beta (C/EBP-β), negatively regulates tumor suppressor miR-145 by directly interacting through the putative C/EBP-β binding site present in the miR-145 promoter. It was also shown that resveratrol treatment resulted in the decreased activation of C/EBP-β which subsequently induced the expression of miR-145 in breast cancer cells [101]. Androgen receptor (AR) directly regulates miR-21 by binding to the miR-21 promoter in prostate cancer [102]; Siddiqui and coworkers (2011) demonstrated that EGCG inhibited prostate cancer cell growth by decreasing the level of AR and miR-21 [63]. A study conducted by Hagiwara and coworkers has shown that resveratrol transcriptionally upregulated the expression of several tumor suppressor miRNAs such as miR-141, miR-26a, miR-195, miR-126, miR-340, miR-34a, miR-193b, miR-335, miR-200c, miR-497, miR-196a, and miR-125a-3p in MDA-MB-231 breast cancer cells [58]. It is known that p53 is a tumor suppressor gene and a transcription factor which functions by either causing growth arrest or inducing apoptosis [103]. Emerging data suggest that p53 transcriptionally regulates several miRNAs [104]. A number of studies have shown that curcumin regulates the expression of several miRNAs that are transcriptional targets of p53 such as miR-22, miR-15/16a, miR-34, and miR-21 [80, 83, 105–108]. Considering all these observations, it is speculated that curcumin regulates the expression of p53, which in turn modulates the expression of several miRNAs.

5.2. Epigenetic Regulation of miRNAs

Epigenetic regulation is defined as modifications of the genome without any change to the nucleotide sequence. Supporting evidence suggests that epigenetic modification, like aberrant CpG methylation or histone modifications, contributes to the dysregulation of gene expression in tumor cells. Pharmacologic inhibition of DNA methyltransferase (DNMT) causes DNA demethylation and upregulates the expression of miRNAs. Saini and coworkers provided evidence that curcumin treatment resulted in the hypomethylation of miR-203 promoter and subsequent upregulation of miR-203, which is epigenetically silenced in various malignancies [81]. Treatment with a curcumin analogue, difluorinated curcumin, restored the expression of miR-34a and miR-34c by working as a demethylating agent in colon cancer cells [109]. Rabiau and coworkers performed miRNA expression profiling following the treatment with the flavonoids genistein and daidzein in prostate cancer cells [110]. Their investigation revealed a significant upregulation of miR-548b-5p in PC3 and miR-15a in LNCaP cells by genistein and daidzein through regulation at the epigenetic level [110]. Zaman et al. demonstrated that miR-145 is inactivated as a result of its promoter methylation in prostate cancer; treatment with genistein demethylated the promoter of miR-145 which resulted in an increased level of miR-145 [111]. In a separate study on prostate cancer, isoflavone efficiently demethylated the promoter region of miR-29a and miR-1256 and subsequently upregulated their expression [112]. All these observations suggest the significant role of phytochemicals in the regulation of miRNAs at the epigenetic level (Figure 1).

5.3. Regulation of miRNA Processing by Phytochemicals

miRNA processing can be regulated at various steps, and any alteration in processing either increases or decreases the level of miRNAs [113]. The role of phytochemical-modulated expression of miRNAs through the regulation of proteins involved in miRNA processing has been recently investigated, as shown in Figure 1. Hagiwara and coworkers investigated and reported that resveratrol treatment significantly increased the expression of Ago2 and results in enhanced levels of tumor suppressor miRNAs such as miR-16, miR-141, miR-143, and miR-200c in MDA-MB-231 cells [58]. Moreover, resveratrol treatment resulted in the enhanced level of miR-663 and pre-miR-663 by interfering with the drosha mediated processing of pri-miR-663 that resulted in the inhibition of miR-155, which is overexpressed in many cancers [114]. These studies provide evidence that phytochemicals regulate the expression of miRNAs epigenetically and transcriptionally and by controlling miRNA processing.

6. Conclusion and Future Perspective

miRNAs are a novel class of gene regulators. Thus far, we have only been able to see just a small part of the complexity of cellular regulation by miRNAs with regard to all of the different functions that miRNAs can perform. miRNAs are aberrantly expressed in most cancers and this has been correlated throughout cancer initiation and progression; hence, miRNAs represent very attractive and novel targets for cancer therapy. Phytochemicals display an inimitable ability to alter the level of miRNAs involved in regulation of cancer pathobiology by modulating the expression of miRNAs through a variety of mechanisms, namely, epigenetic, transcriptional, and miRNA processing. In addition, phytochemicals increase the chemosensitivity of conventional therapeutic drugs through modulating miRNAs. As a result, phytochemicals can be exploited for designing therapeutic approaches in combination with conventional therapies to improve cancer treatment and prevention strategies. Despite the potent anticancer activities of phytochemicals, there are some concerns such as specific targeting and bioavailability. To overcome these hurdles in the use of phytochemicals, different approaches are being explored, namely, chemical modification, synthetic formulation, delivery by nanoparticles, and so forth. Hence, there is a wide scope for the development of phytochemicals into commercial drugs to efficaciously prevent and treat cancer.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

Ajay P. Singh received Grants nos. CA137513, CA167137, CA175772, and CA185490 and Seema Singh received Grant no. CA169829 by NIH/NCI. Ajay P. Singh received Grants nos. PC110545 and PC0739930 by DOD/US Army, and internal funding support from USAMCI.

References

A. Bhardwaj, S. Singh, and A. P. Singh, “MicroRNA-based cancer therapeutics: big hope from small RNAs,” Molecular and Cellular Pharmacology, vol. 2, no. 5, pp. 213–219, 2010.
View at: Publisher Site | Google Scholar
M. R. Friedländer, E. Lizano, A. J. S. Houben et al., “Evidence for the biogenesis of more than 1,000 novel human microRNAs,” Genome Biology, vol. 15, no. 4, article R57, 2014.
View at: Publisher Site | Google Scholar
S. Srivastava, A. Bhardwaj, S. Leavesley, W. Grizzle, S. Singh, and A. Singh, “MicroRNAs as potential clinical biomarkers: emerging approaches for their detection,” Biotechnic & Histochemistry, vol. 88, no. 7, pp. 373–387, 2013.
View at: Publisher Site | Google Scholar
S. K. Srivastava, S. Arora, S. Singh, A. Bhardwaj, C. Averett, and A. P. Singh, “MicroRNAs in pancreatic malignancy: progress and promises,” Cancer Letters, vol. 347, no. 2, pp. 167–174, 2014.
View at: Publisher Site | Google Scholar
G. Block, B. Patterson, and A. Subar, “Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence,” Nutrition and Cancer, vol. 18, no. 1, pp. 1–29, 1992.
View at: Publisher Site | Google Scholar
L. Reddy, B. Odhav, and K. D. Bhoola, “Natural products for cancer prevention: a global perspective,” Pharmacology and Therapeutics, vol. 99, no. 1, pp. 1–13, 2003.
View at: Publisher Site | Google Scholar
K. A. Steinmetz and J. D. Potter, “Vegetables, fruit, and cancer prevention: a review,” Journal of the American Dietetic Association, vol. 96, no. 10, pp. 1027–1039, 1996.
View at: Publisher Site | Google Scholar
M. Russo, C. Spagnuolo, I. Tedesco, and G. L. Russo, “Phytochemicals in cancer prevention and therapy: truth or dare?” Toxins, vol. 2, no. 4, pp. 517–551, 2010.
View at: Publisher Site | Google Scholar
C. V. Rao, C.-X. Wang, B. Simi et al., “Enhancement of experimental colon cancer by genistein,” Cancer Research, vol. 57, no. 17, pp. 3717–3722, 1997.
View at: Google Scholar
D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the last 25 years,” Journal of Natural Products, vol. 70, no. 3, pp. 461–477, 2007.
View at: Publisher Site | Google Scholar
G. L. Russo, “Ins and outs of dietary phytochemicals in cancer chemoprevention,” Biochemical Pharmacology, vol. 74, no. 4, pp. 533–544, 2007.
View at: Publisher Site | Google Scholar
Y. H. Siddique, G. Ara, T. Beg, J. Gupta, and M. Afzal, “Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes,” Experimental and Toxicologic Pathology, vol. 62, no. 5, pp. 503–508, 2010.
View at: Publisher Site | Google Scholar
W. Tan, J. Lu, M. Huang et al., “Anti-cancer natural products isolated from chinese medicinal herbs,” Chinese Medicine, vol. 6, article 27, 2011.
View at: Publisher Site | Google Scholar
N. Tyagi and P. C. Ghosh, “Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes,” European Journal of Pharmaceutical Sciences, vol. 43, no. 4, pp. 343–353, 2011.
View at: Publisher Site | Google Scholar
N. Tyagi, S. S. Rathore, and P. C. Ghosh, “Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin,” Drug Delivery, vol. 18, no. 6, pp. 394–404, 2011.
View at: Publisher Site | Google Scholar
J. Winter, S. Jung, S. Keller, R. I. Gregory, and S. Diederichs, “Many roads to maturity: microRNA biogenesis pathways and their regulation,” Nature Cell Biology, vol. 11, no. 3, pp. 228–234, 2009.
View at: Publisher Site | Google Scholar
S. M. Johnson, H. Grosshans, J. Shingara et al., “RAS is regulated by the let-7 microRNA family,” Cell, vol. 120, no. 5, pp. 635–647, 2005.
View at: Publisher Site | Google Scholar
F. Yu, H. Yao, P. Zhu et al., “let-7 regulates self renewal and tumorigenicity of breast cancer cells,” Cell, vol. 131, no. 6, pp. 1109–1123, 2007.
View at: Publisher Site | Google Scholar
B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “microRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007.
View at: Publisher Site | Google Scholar
M. S. Kumar, S. J. Erkeland, R. E. Pester et al., “Suppression of non-small cell lung tumor development by the let-7 microRNA family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3903–3908, 2008.
View at: Publisher Site | Google Scholar
X.-M. Xia, W.-Y. Jin, R.-Z. Shi, Y.-F. Zhang, and J. Chen, “Clinical significance and the correlation of expression between let-7 and K-ras in non-small cell lung cancer,” Oncology Letters, vol. 1, no. 6, pp. 1045–1047, 2010.
View at: Publisher Site | Google Scholar
A. Cimmino, G. A. Calin, M. Fabbri et al., “miR-15 and miR-16 induce apoptosis by targeting BCL2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13944–13949, 2005.
View at: Publisher Site | Google Scholar
L. Xia, D. Zhang, R. Du et al., “miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells,” International Journal of Cancer, vol. 123, no. 2, pp. 372–379, 2008.
View at: Publisher Site | Google Scholar
F. Takeshita, L. Patrawala, M. Osaki et al., “Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes,” Molecular Therapy, vol. 18, no. 1, pp. 181–187, 2010.
View at: Publisher Site | Google Scholar
T.-C. Chang, E. A. Wentzel, O. A. Kent et al., “Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis,” Molecular Cell, vol. 26, no. 5, pp. 745–752, 2007.
View at: Publisher Site | Google Scholar
A. Javeri, M. Ghaffarpour, M. F. Taha, and M. Houshmand, “Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis,” Medical Oncology, vol. 30, no. 1, article 413, 2013.
View at: Publisher Site | Google Scholar
Q. Ji, X. Hao, M. Zhang et al., “MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells,” PLoS ONE, vol. 4, no. 8, Article ID e6816, 2009.
View at: Publisher Site | Google Scholar
X. Jiang, H. Huang, Z. Li et al., “miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 47, pp. 19397–19402, 2012.
View at: Publisher Site | Google Scholar
S. K. Srivastava, A. Bhardwaj, S. Singh et al., “MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells,” Carcinogenesis, vol. 32, no. 12, pp. 1832–1839, 2011.
View at: Publisher Site | Google Scholar
S. Arora, S. K. Swaminathan, A. Kirtane et al., “Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy,” International Journal of Nanomedicine, vol. 9, pp. 2933–2942, 2014.
View at: Google Scholar
D. Liu, C. Liu, X. Wang, S. Ingvarsson, and H. Chen, “MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression,” Cancer Epidemiology, vol. 38, no. 1, pp. 85–92, 2014.
View at: Publisher Site | Google Scholar
X. Liu, X. Zhang, J. Xiang, Y. Lv, and J. Shi, “miR-451: potential role as tumor suppressor of human hepatoma cell growth and invasion,” International Journal of Oncology, vol. 45, pp. 739–745, 2014.
View at: Google Scholar
G. Lv, Z. Hu, Y. Tie et al., “MicroRNA-451 regulates activating transcription factor 2 expression and inhibits liver cancer cell migration,” Oncology Reports, vol. 32, no. 3, pp. 1021–1028, 2014.
View at: Publisher Site | Google Scholar
O. Kovalchuk, J. Filkowski, J. Meservy et al., “Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2152–2159, 2008.
View at: Publisher Site | Google Scholar
D. Xu, Q. Wang, Y. An, and L. Xu, “MiR-203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin,” Molecular Medicine Reports, vol. 8, no. 2, pp. 379–384, 2013.
View at: Publisher Site | Google Scholar
L. Zhang and G. Coukos, “MicroRNAs: a new insight into cancer genome,” Cell Cycle, vol. 5, no. 19, pp. 2216–2219, 2006.
View at: Publisher Site | Google Scholar
L. He, J. M. Thomson, M. T. Hemann et al., “A microRNA polycistron as a potential human oncogene,” Nature, vol. 435, no. 7043, pp. 828–833, 2005.
View at: Publisher Site | Google Scholar
Y. Ma, S. Yu, W. Zhao, Z. Lu, and J. Chen, “miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2,” Cancer Letters, vol. 298, no. 2, pp. 150–158, 2010.
View at: Publisher Site | Google Scholar
P. P. Medina, M. Nolde, and F. J. Slack, “OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma,” Nature, vol. 467, no. 7311, pp. 86–90, 2010.
View at: Publisher Site | Google Scholar
F. Sicard, M. Gayral, H. Lulka, L. Buscail, and P. Cordelier, “Targeting miR-21 for the therapy of pancreatic cancer,” Molecular Therapy, vol. 21, no. 5, pp. 986–994, 2013.
View at: Publisher Site | Google Scholar
Y. Li, L. Yan, W. Zhang et al., “miR-21 inhibitor suppresses proliferation and migration of nasopharyngeal carcinoma cells through down-regulation of BCL2 expression,” International Journal of Clinical and Experimental Pathology, vol. 7, pp. 3478–3487, 2014.
View at: Google Scholar
S. Costinean, N. Zanesi, Y. Pekarsky et al., “Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 7024–7029, 2006.
View at: Publisher Site | Google Scholar
Q. Huang, K. Gumireddy, M. Schrier et al., “The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis,” Nature Cell Biology, vol. 10, no. 2, pp. 202–210, 2008.
View at: Publisher Site | Google Scholar
K. Yang, A. M. Handorean, and K. A. Iczkowski, “MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro,” International Journal of Clinical and Experimental Pathology, vol. 2, no. 4, pp. 361–369, 2009.
View at: Google Scholar
K. Wu, G. Hu, X. He et al., “MicroRNA-424-5p suppresses the expression of socs6 in pancreatic cancer,” Pathology & Oncology Research, vol. 19, no. 4, pp. 739–748, 2013.
View at: Publisher Site | Google Scholar
Y. Liu, M. Li, G. Zhang, and Z. Pang, “MicroRNA-10b overexpression promotes non-small cell lung cancer cell proliferation and invasion,” European Journal of Medical Research, vol. 18, no. 1, article 41, 2013.
View at: Publisher Site | Google Scholar
L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, “Tumour invasion and metastasis initiated by microRNA-10b in breast cancer,” Nature, vol. 449, no. 7163, pp. 682–688, 2007.
View at: Publisher Site | Google Scholar
H. Xiao, H. Li, G. Yu et al., “MicroRNA-10b promotes migration and invasion through KLF4 and HOXD10 in human bladder cancer,” Oncology Reports, vol. 31, pp. 1832–1838, 2014.
View at: Google Scholar
A. Ahmad, S. Sethi, W. Chen, R. Ali-Fehmi, S. Mittal, and F. H. Sarkar, “Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis,” The American Journal of Translational Research, vol. 6, pp. 384–390, 2014.
View at: Google Scholar
M. S. Hwang, N. Yu, S. Y. Stinson et al., “miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer,” PLoS ONE, vol. 8, no. 6, Article ID e66502, 2013.
View at: Publisher Site | Google Scholar
S. Mardente, E. Mari, F. Consorti et al., “HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells,” Oncology Reports, vol. 28, no. 6, pp. 2285–2289, 2012.
View at: Publisher Site | Google Scholar
R. Nassirpour, P. P. Mehta, S. M. Baxi, and M.-J. Yin, “miR-221 promotes tumorigenesis in human triple negative breast cancer cells,” PLoS ONE, vol. 8, no. 4, Article ID e62170, 2013.
View at: Publisher Site | Google Scholar
X. Yang, Y. Yang, R. Gan et al., “Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1,” PLoS ONE, vol. 9, no. 6, Article ID e98833, 2014.
View at: Publisher Site | Google Scholar
T. E. Miller, K. Ghoshal, B. Ramaswamy et al., “MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1,” The Journal of Biological Chemistry, vol. 283, no. 44, pp. 29897–29903, 2008.
View at: Publisher Site | Google Scholar
A. Bishayee, T. Politis, and A. S. Darvesh, “Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma,” Cancer Treatment Reviews, vol. 36, no. 1, pp. 43–53, 2010.
View at: Publisher Site | Google Scholar
M. Athar, J. H. Back, X. Tang et al., “Resveratrol: a review of preclinical studies for human cancer prevention,” Toxicology and Applied Pharmacology, vol. 224, no. 3, pp. 274–283, 2007.
View at: Publisher Site | Google Scholar
E. Tili, J. J. Michaille, H. Alder et al., “Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells,” Biochemical Pharmacology, vol. 80, no. 12, pp. 2057–2065, 2010.
View at: Publisher Site | Google Scholar
K. Hagiwara, N. Kosaka, Y. Yoshioka, R. U. Takahashi, F. Takeshita, and T. Ochiya, “Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity,” Scientific Reports, vol. 2, article 314, 2012.
View at: Publisher Site | Google Scholar
P. Liu, H. Liang, Q. Xia et al., “Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression,” Clinical and Translational Oncology, vol. 15, no. 9, pp. 741–746, 2013.
View at: Publisher Site | Google Scholar
T. Bai, D.-S. Dong, and L. Pei, “Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer,” Oncology Reports, vol. 31, no. 5, pp. 2293–2297, 2014.
View at: Publisher Site | Google Scholar
M. Kumazaki, S. Noguchi, Y. Yasui et al., “Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells,” Journal of Nutritional Biochemistry, vol. 24, no. 11, pp. 1849–1858, 2013.
View at: Publisher Site | Google Scholar
W. P. Tsang and T. T. Kwok, “Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells,” The Journal of Nutritional Biochemistry, vol. 21, no. 2, pp. 140–146, 2010.
View at: Publisher Site | Google Scholar
I. A. Siddiqui, M. Asim, B. B. Hafeez, V. M. Adhami, R. S. Tarapore, and H. Mukhtar, “Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer,” The FASEB Journal, vol. 25, no. 4, pp. 1198–1207, 2011.
View at: Publisher Site | Google Scholar
H. Wang, S. Bian, and C. S. Yang, “Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1 $α$ ,” Carcinogenesis, vol. 32, no. 12, pp. 1881–1889, 2011.
View at: Publisher Site | Google Scholar
D.-H. Zhou, X. Wang, and Q. Feng, “EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells,” Nutrition and Cancer, vol. 66, no. 4, pp. 636–644, 2014.
View at: Publisher Site | Google Scholar
M. Chakrabarti, W. Ai, N. L. Banik, and S. K. Ray, “Overexpression of miR-7-1 increases efficacy of green tea polyphenols for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-DZ cells,” Neurochemical Research, vol. 38, no. 2, pp. 420–432, 2013.
View at: Publisher Site | Google Scholar
E. Salerno, B. J. Scaglione, F. D. Coffman et al., “Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity,” Molecular Cancer Therapeutics, vol. 8, no. 9, pp. 2684–2692, 2009.
View at: Publisher Site | Google Scholar
Y. Chen, M. S. Zaman, G. Deng et al., “MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer,” Cancer Prevention Research, vol. 4, no. 1, pp. 76–86, 2011.
View at: Publisher Site | Google Scholar
T. Chiyomaru, S. Yamamura, M. S. Zaman et al., “Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151,” PLoS ONE, vol. 7, no. 8, Article ID e43812, 2012.
View at: Publisher Site | Google Scholar
L. Xu, J. Xiang, J. Shen et al., “Oncogenic microRNA-27a is a target for genistein in ovarian cancer cells,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 7, pp. 1126–1132, 2013.
View at: Publisher Site | Google Scholar
T. Chiyomaru, S. Yamamura, S. Fukuhara et al., “Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer,” PLoS ONE, vol. 8, no. 3, Article ID e58929, 2013.
View at: Publisher Site | Google Scholar
H. Hirata, K. Ueno, K. Nakajima et al., “Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells,” British Journal of Cancer, vol. 108, no. 10, pp. 2070–2078, 2013.
View at: Publisher Site | Google Scholar
J. Ma, L. Cheng, H. Liu et al., “Genistein down-regulates miR-223 expression in pancreatic cancer cells,” Current Drug Targets, vol. 14, no. 10, pp. 1150–1156, 2013.
View at: Publisher Site | Google Scholar
J. Xia, L. Cheng, C. Mei et al., “Genistein inhibits cell growth and invasion through regulation of MiR-27a in pancreatic cancer cells,” Current Pharmaceutical Design, vol. 20, no. 33, pp. 5348–5353, 2014.
View at: Publisher Site | Google Scholar
G. N. Asher and K. Spelman, “Clinical utility of curcumin extract,” Alternative Therapies in Health and Medicine, vol. 19, no. 2, pp. 20–22, 2013.
View at: Google Scholar
T. O. Khor, Y.-S. Keum, W. Lin et al., “Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice,” Cancer Research, vol. 66, no. 2, pp. 613–621, 2006.
View at: Publisher Site | Google Scholar
X.-D. Sun, X.-E. Liu, and D.-S. Huang, “Curcumin reverses the epithelial-mesenchymal transition of pancreatic cancer cells by inhibiting the Hedgehog signaling pathway,” Oncology Reports, vol. 29, no. 6, pp. 2401–2407, 2013.
View at: Publisher Site | Google Scholar
H. K. Vyas, R. Pal, R. Vishwakarma, N. K. Lohiya, and G. P. Talwar, “Selective killing of leukemia and lymphoma cells ectopically expressing hCGβ by a conjugate of curcumin with an antibody against hCG $β$ subunit,” Oncology, vol. 76, no. 2, pp. 101–111, 2009.
View at: Publisher Site | Google Scholar
S. Reuter, S. C. Gupta, B. Park, A. Goel, and B. B. Aggarwal, “Epigenetic changes induced by curcumin and other natural compounds,” Genes and Nutrition, vol. 6, no. 2, pp. 93–108, 2011.
View at: Publisher Site | Google Scholar
J. Yang, Y. Cao, J. Sun, and Y. Zhang, “Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells,” Medical Oncology, vol. 27, no. 4, pp. 1114–1118, 2010.
View at: Publisher Site | Google Scholar
S. Saini, S. Arora, S. Majid et al., “Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer,” Cancer Prevention Research, vol. 4, no. 10, pp. 1698–1709, 2011.
View at: Publisher Site | Google Scholar
J. Zhang, Y. Du, C. Wu et al., “Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-¹⁸⁶* signaling pathway,” Oncology Reports, vol. 24, no. 5, pp. 1217–1223, 2010.
View at: Publisher Site | Google Scholar
G. Mudduluru, J. N. George-William, S. Muppala et al., “Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer,” Bioscience Reports, vol. 31, no. 3, pp. 185–197, 2011.
View at: Publisher Site | Google Scholar
S. F. Zhao, X. Zhang, X. J. Zhang, X. Q. Shi, Z. J. Yu, and Q. C. Kan, “Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 15, pp. 3363–3368, 2014.
View at: Google Scholar
E. Kronski, M. E. Fiori, O. Barbieri et al., “MiR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2,” Molecular Oncology, vol. 8, no. 3, pp. 581–595, 2014.
View at: Publisher Site | Google Scholar
S. Sarkar, H. Dubaybo, S. Ali et al., “Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA,” American Journal of Cancer Research, vol. 3, no. 5, pp. 465–477, 2013.
View at: Google Scholar
T. K. Lam, S. Shao, Y. Zhao et al., “Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 12, pp. 2176–2184, 2012.
View at: Publisher Site | Google Scholar
A. Del Follo-Martinez, N. Banerjee, X. Li, S. Safe, and S. Mertens-Talcott, “Resveratrol and quercetin in combination have anticancer activity in colon cancer cells and repress oncogenic microRNA-27a,” Nutrition and Cancer, vol. 65, no. 3, pp. 494–504, 2013.
View at: Publisher Site | Google Scholar
M. Appari, K. R. Babu, A. Kaczorowski, W. Gross, and I. Herr, “Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition,” International Journal of Oncology, vol. 45, no. 4, pp. 1391–1400, 2014.
View at: Publisher Site | Google Scholar
C. G. Moertel, A. J. Schutt, R. J. Reitemeier, and R. G. Hahn, “Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer,” Cancer Chemotherapy Reports, vol. 56, no. 1, pp. 95–101, 1972.
View at: Google Scholar
H. Ulukan and P. W. Swaan, “Camptothecins: a review of their chemotherapeutic potential,” Drugs, vol. 62, no. 14, pp. 2039–2057, 2002.
View at: Publisher Site | Google Scholar
C.-W. Zeng, X.-J. Zhang, K.-Y. Lin et al., “Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways,” Molecular Pharmacology, vol. 81, no. 4, pp. 578–586, 2012.
View at: Publisher Site | Google Scholar
D. Bertozzi, J. Marinello, S. G. Manzo, F. Fornari, L. Gramantieri, and G. Capranico, “The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells,” Molecular Cancer Therapeutics, vol. 13, no. 1, pp. 239–248, 2013.
View at: Publisher Site | Google Scholar
D. M. Minich and J. S. Bland, “A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals,” Nutrition Reviews, vol. 65, no. 6, pp. 259–267, 2007.
View at: Publisher Site | Google Scholar
Y. Li, T. G. Vandenboom II, D. Kong et al., “Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells,” Cancer Research, vol. 69, no. 16, pp. 6704–6712, 2009.
View at: Publisher Site | Google Scholar
Y. Li, T. G. VandenBoom, Z. Wang et al., “miR-146a suppresses invasion of pancreatic cancer cells,” Cancer Research, vol. 70, no. 4, pp. 1486–1495, 2010.
View at: Publisher Site | Google Scholar
Y. Jin, “3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation,” Molecular and Cellular Biochemistry, vol. 358, no. 1-2, pp. 345–354, 2011.
View at: Publisher Site | Google Scholar
S. Deng, G. A. Calin, C. M. Croce, G. Coukos, and L. Zhang, “Mechanisms of microRNA deregulation in human cancer,” Cell Cycle, vol. 7, no. 17, pp. 2643–2646, 2008.
View at: Publisher Site | Google Scholar
B. W. Ozanne, L. McGarry, H. J. Spence et al., “Transcriptional regulation of cell invasion: AP-1 regulation of a multigenic invasion programme,” European Journal of Cancer, vol. 36, no. 13, pp. 1640–1648, 2000.
View at: Publisher Site | Google Scholar
A. Misawa, R. Katayama, S. Koike, A. Tomida, T. Watanabe, and N. Fujita, “AP-1-dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells,” Oncology Research, vol. 19, no. 1, pp. 23–33, 2010.
View at: Publisher Site | Google Scholar
M. Sachdeva, Q. Liu, J. Cao, Z. Lu, and Y.-Y. Mo, “Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells,” Nucleic Acids Research, vol. 40, no. 14, pp. 6683–6692, 2012.
View at: Publisher Site | Google Scholar
J. Ribas, X. Ni, M. Haffner et al., “miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth,” Cancer Research, vol. 69, no. 18, pp. 7165–7169, 2009.
View at: Publisher Site | Google Scholar
L. Boominathan, “The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex,” PLoS ONE, vol. 5, no. 5, Article ID e10615, 2010.
View at: Publisher Site | Google Scholar
M. Yamakuchi, C. D. Lotterman, C. Bao et al., “P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 14, pp. 6334–6339, 2010.
View at: Publisher Site | Google Scholar
X. Ma, S. N. Choudhury, X. Hua, Z. Dai, and Y. Li, “Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway,” Carcinogenesis, vol. 34, no. 6, pp. 1216–1223, 2013.
View at: Publisher Site | Google Scholar
S. Sreenivasan, K. Thirumalai, R. Danda, and S. Krishnakumar, “Effect of curcumin on miRNA expression in human Y79 retinoblastoma cells,” Current Eye Research, vol. 37, no. 5, pp. 421–428, 2012.
View at: Publisher Site | Google Scholar
D. Subramaniam, S. Ponnurangam, P. Ramamoorthy et al., “Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling,” PLoS ONE, vol. 7, no. 2, Article ID e30590, 2012.
View at: Publisher Site | Google Scholar
M. Yamakuchi and C. J. Lowenstein, “MiR-34, SIRT1 and p53: the feedback loop,” Cell Cycle, vol. 8, no. 5, pp. 712–715, 2009.
View at: Publisher Site | Google Scholar
S. Roy, E. Levi, A. P. Majumdar, and F. H. Sarkar, “Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF,” Journal of Hematology & Oncology, vol. 5, article 58, 2012.
View at: Publisher Site | Google Scholar
N. Rabiau, H.-K. Trraf, M. Adjakly et al., “miRNAs differentially expressed in prostate cancer cell lines after soy treatment,” In Vivo, vol. 25, no. 6, pp. 917–921, 2011.
View at: Google Scholar
M. S. Zaman, Y. Chen, G. Deng et al., “The functional significance of microRNA-145 in prostate cancer,” British Journal of Cancer, vol. 103, no. 2, pp. 256–264, 2010.
View at: Publisher Site | Google Scholar
Y. Li, D. Kong, A. Ahmad, B. Bao, G. Dyson, and F. H. Sarkar, “Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion,” Epigenetics, vol. 7, no. 8, pp. 940–949, 2012.
View at: Publisher Site | Google Scholar
I. Slezak-Prochazka, D. Selvi, B.-J. Kroesen, and A. Van Den Berg, “MicroRNAs, macrocontrol: regulation of miRNA processing,” RNA, vol. 16, no. 6, pp. 1087–1095, 2010.
View at: Publisher Site | Google Scholar
E. Tili, J.-J. Michaille, B. Adair et al., “Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD,” Carcinogenesis, vol. 31, no. 9, pp. 1561–1566, 2010.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2015 Sanjeev K. Srivastava et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

4065

Downloads

1677

Citations